- Home
- DXLG vs CGTX Comparison
DXLG vs CGTX Comparison
Compare DXLG & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXLG | CGTX |
|---|---|---|
| Founded | 1976 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2M | 94.5M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DXLG | CGTX |
|---|---|---|
| Price | $0.51 | $1.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.50 | ★ $3.33 |
| AVG Volume (30 Days) | 127.3K | ★ 698.2K |
| Earning Date | 04-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $467,015,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.49 | $0.22 |
| 52 Week High | $2.11 | $3.83 |
Technical Indicators
Market Signals| Indicator | DXLG | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.43 | 42.30 |
| Support Level | N/A | $1.00 |
| Resistance Level | $0.73 | $1.21 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 14.45 | 27.50 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.